AIP summarizes the triglyceride-to-HDL relationship on a logarithmic scale. Higher values suggest a more atherogenic lipid phenotype and may indicate increased residual cardiovascular risk.

Use AIP as an adjunctive lipid-risk marker in patients with mixed dyslipidemia, metabolic syndrome traits, or discordant traditional lipid markers.

AIP is not currently the primary treatment target in major lipid guidelines. It should be interpreted as a supplementary marker alongside standard lipid and clinical risk metrics.